Transmembrane nfat inhibitory peptide

Details Transmembrane nfat inhibitory peptide Transmembrane nfat inhibitory peptide

2007-01-09

2007-01-09

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C530S300000, C530S324000, C530S326000

Reexamination Certificate

active

10504333

ABSTRACT:
The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.

REFERENCES:
patent: 5981279 (1999-11-01), Weiss
patent: 6982082 (2006-01-01), Schreiber et al.
patent: 2002-153288 (2002-05-01), None
patent: WO 01/43694 (2001-06-01), None
patent: WO 03/006619 (2003-01-01), None
C. Loh, et al. J. Biol. Chem. (1996) 271(18) pp. 10884-10891.
E.S. Scott, et al. J. Virol. (2001) 75(20) pp. 9955-9965.
M. Matsushita, et al. J. Neurosci. (2001) 21(16), pp. 6000-6007.
A.M. Ho, et al. J. Biol. Chem. (1994) 269(45), pp. 28181-28186.
T.C. Foster, et al. J. Neurosci. (2001) 21(11), pp. 4066-4073.
Aramburu J. et al., “Affinity-Driven Peptide Selection of an NFAT Inhibitor More Selective Than Cyclosporin A”, Science, American Association for the Advancement of Science, US, vol. 285, Sep. 24, 1999, pp. 2129-2133, XP 002939935.
Lindgren M. et al., “Cell-Penetrating Peptides”, Trends in Pharmacological Sciences, Elsevier, Haywarth, GB, vol. 21, No. 3, Mar. 2000, pp. 99-103, XP002290884.
Noguchi H. et al., “A New Cell-Permeable Peptide Allows Successful Allogeneic Islet Transplantation in Mice”, Nature Medicine, vol. 10, No. 3, Mar. 2004, pp. 305-309, XP002351236.
Supplementary European Search Report dated Nov. 9, 2005.

Affiliated with

Also associated with

Rating

Transmembrane nfat inhibitory peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transmembrane nfat inhibitory peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transmembrane nfat inhibitory peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3734972